Pfizer Inc. (NYSE:PFE) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Pfizer Inc. (NYSE:PFE) announced positive results from its Phase 3 HER2CLIMB-05 trial. ​The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer.

Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged PFS in patients with advanced breast cancer: New York Monday, April 7, 2014, 18:00 Hrs [IST]

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder cancer (NMIBC) suggest the PD-L1 inhibitor measures up to Pfizer’s PD-1 candidate sasanlimab.

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will evaluate the safety and efficacy of the treatment in children ...

Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger.

The study will examine vaccine safety, efficacy and immunity at lower doses. Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical company announced Tuesday. Based on safety, efficacy and ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical trial titled An Open-Label Study in